Introduction and Objective: Assess Omnipod 5 System’s efficacy in managing glycemia during activity, comparing ‘Activity Feature’ initiated 30 (AF-30) or 60 min (AF-60) before exercise to automated delivery (Auto).

Methods: In this three-way crossover, 50 people with T1D (age 30±15 years, BMI 24.7±4.1 kg/m2, HbA1c 7.5±1.0%, and T1D duration 16±11 years) underwent a 70 min activity session (60 min exercise, 5 min rest at 20 and 45 min), 3hrs post-bolus, under each condition (Auto, AF-30, and AF-60). Pre-activity glucose was 90-200mg/dL. Up to 16g of carbs were provided if glucose was <90mg/dL pre activity or <70mg/dL during activity. Metrics were assessed using generalized estimating equations.

Results: Insulin delivery was decreased before and during activity for AF-30 and AF-60 vs Auto (p<0.05, Table). During activity, AF-30 and AF-60 had smaller decreases in glucose, which was significant for Auto vs AF-30, p=0.03. Carb consumption during activity was higher for Auto vs AF-30 (p=0.02) and AF-60 (p=0.04). Time to hypo was delayed by 10 min (16% longer) in AF-30 and AF-60 relative to Auto.

Conclusion: Enabling Activity Feature 30 min before activity with Omnipod 5 may effectively mitigate glucose declines. Regardless, carb consumption may be necessary to minimize hypo risk during 60 min of exercise.

graphic
View largeDownload slide
Disclosure

L.V. Turner: None. J.L. Sherr: Consultant; Medtronic. Advisory Panel; Medtronic, Insulet Corporation. Speaker's Bureau; Insulet Corporation. Advisory Panel; Vertex Pharmaceuticals Incorporated, MannKind Corporation, StartUp Health T1D Moonshot, Bigfoot Biomedical, Inc., Cecelia Health. Speaker's Bureau; Zealand Pharma A/S. D.P. Zaharieva: Research Support; Leona M. and Harry B. Helmsley Charitable Trust. Advisory Panel; Dexcom, Inc. Research Support; Insulet Corporation. Speaker's Bureau; Dexcom, Inc. Research Support; International Society for Pediatric and Adolescent Diabetes. Board Member; Juvenile Diabetes Research Foundation (JDRF). J.D. Baran: None. B.W. Bode: Research Support; Omnipod. Speaker's Bureau; Omnipod. Research Support; Medtronic. Advisory Panel; Medtronic. S.A. Brown: Research Support; Dexcom, Inc., Tandem Diabetes Care, Inc., Insulet Corporation, Tolerion, Roche Diagnostics. S. Bzdick: None. M. Church: None. D.W. Hansen: None. R.S. Kingman: None. L.M. Laffel: Consultant; Dexcom, Inc. Advisory Panel; Medscape, Medtronic, Vertex Pharmaceuticals Incorporated. Consultant; Novo Nordisk. Advisory Panel; Lilly Diabetes, Provention Bio, Inc., Sanofi-Aventis U.S., Janssen Pharmaceuticals, Inc., MannKind Corporation. V.N. Shah: Consultant; Dexcom, Inc., Insulet Corporation. Research Support; Insulet Corporation. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Sanofi, Medscape. Consultant; embecta, Tandem Diabetes Care, Inc. S.L. Stone: None. T. Vienneau: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. L.M. Huyett: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. B. Dumais: None. T.T. Ly: Employee; Insulet Corporation. M.C. Riddell: Consultant; Eli Lilly and Company. Speaker's Bureau; Novo Nordisk. Advisory Panel; Supersapiens. Consultant; Dexcom, Inc. Speaker's Bureau; Sanofi. Advisory Panel; Zealand Pharma A/S. Speaker's Bureau; Dexcom, Inc. Stock/Shareholder; Zucara Therapeutics.

Funding

This study was funded by Insulet Corporation.

© 2024 by the American Diabetes Association
2024
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.